RBC Capital reports based on an update in the FDA’s Orange Book that Intra-Cellular has now received a patent extension for their ‘839 patent that would bring this Caplyta patent to August 2033, or February 2034 with the likely additional pediatric extension. The firm, which says IP life “has been an important question surrounding Caplyta’s long-term cash flow generation,” has an Outperform rating and $79 price target on Intra-Cellular shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ITCI:
- Intra-Cellular announces presentations at Psych Congress 2023
- Intra-Cellular Therapies Announces Presentations at Psych Congress 2023 Including Positive Results from Study 403 in Mixed Features
- Intra-Cellular Therapies to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
- Intra-Cellular Therapies to Present at the Canaccord Genuity 43rd Annual Growth Conference
- Intra-Cellular price target raised to $98 from $90 at Cantor Fitzgerald